51.8 F
Santa Barbara
HomeBooksArtificial Tears Market Growth Accelerating with Increasing Prevalence of Dry Eye Syndrome...

Artificial Tears Market Growth Accelerating with Increasing Prevalence of Dry Eye Syndrome and Development in Clinical Research

The global artificial tears market size was valued at US$ 3.3 billion in 2023 & is projected to reach US$ 5.8 billion by 2034, exhibiting a CAGR of 5.4% in forecast period 2024 to 2034.

NEWARK, Del, Nov. 22, 2023 (GLOBE NEWSWIRE) — According to a new report by Future Market Insights, the global artificial tears market was valued at over US$ 3.4 billion in 2024 and is projected to grow at a compound annual growth rate of 5.4% over the course of the forecast period.

The healthcare industry is experiencing significant changes to develop a robust system to improve eye care. Nanomicellular technology is a strong system used in artificial tears production. These are utilized as pharmaceutical carriers for dissolving hydrophobic medications.

Get a Sample Copy of the Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-18329

Substances like povidone simulate mucin’s function, tears’ adhesion to the ocular surface, and the component of the inner tear. Due to prolonged exposure to blue light emitted from digital screens, higher use of mobile phones, rising pollution levels, and dry weather spells, there has been a significant increase in dry eye symptoms among persons in their teens and 20s during the past five years.

Increasing strategic activities among key players and rising focus toward developing new artificial tears are expected to witness an advancement over the forecast period,” opines Sabyasachi Ghosh, Associate Vice President at Future Market Insights (FMI).

Key Takeaways:

  • Glycerine tears are the leading segment of artificial tears and will hold around 26.4% market value share in 2024; glycerine eyes reduce the burning, itching, and feeling that something is in the eyes associated with dry eyes.
  • The solution is set to lead in terms of the dosage form of artificial tears with a projected market value share of around 29.2% by 2034.
  • By formulation, non-preservative-based is leading in the global artificial tears market and is expected to continue to do so with a projected CAGR of 5.6% during the forecasted years with a market share of 55.2% in the year 2024.
  • Dry eye syndrome holds a substantial share of 34.2% in the artificial tears market, with a CAGR of 5.4% during the forecast period. Dry eye syndrome is a multifactorial ocular surface disease brought on by a breakdown in the tear film’s equilibrium.
  • Retail pharmacies as a distribution channel are leading in the global artificial tears market. They are expected to continue to do so with a projected CAGR rate of 4.6% during the forecast years, with a market share of 38.0% in 2024.
  • North America is the leading region with a value share of 30.9% in 2024, owing to the high prevalence of ocular problems such as eye allergies.

Artificial Tears Market Size:

Attribute Details
Forecast Period 2019 to 2023
Historical Data Available for 2024 to 2034
Market Analysis US$ billion for Value
Key Regions Covered North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Countries Covered The United States, Canada, Brazil, Mexico, Argentina, The United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, South Africa and North Africa
Key Market Segments Covered Ingredients, Dosage Form, Route of Administration, Indication, Distribution Channel, and Region
Key Companies Profiled
  • AbbVie, Inc.
  • Akorn, Inc.
  • Alcon
  • Bausch & Lomb
  • Johnson & Johnson
  • Eyevance Pharmaceuticals LLC
  • Ocusoft
  • Santen Pharmaceutical Co. Ltd
  • Similasan Corporation
  • Sun Pharmaceutical Industries Ltd
  • Ursapharm Arzneimittel GmbH
  • Novartis International AG
  • AFT Pharmaceuticals
  • Allergan plc
  • Rohto Pharmaceutical Co., Ltd
  • VISUfarma
  • Otsuka Pharmaceutical Co., Ltd.
  • NovaMedica LLC
  • ENTOD Research Cell UK Ltd
  • OASIS Medical, Inc
  • Abbott Medical Optics Inc
Pricing Available upon Request

Market Competition

The market for artificial tears is fragmented, and several local, upcoming, and established players exist within the market. Key players have initiated marketing initiatives to educate the elderly population about the benefits of artificial tears while also attempting to improve the drugs with different specifications.

  • On 7 October 2019, Allergan plc announced three new over-the-counter (OTC) products: REFRESH RELIEVA, REFRESH RELIEVA PF (preservative-free) multidose, and REFRESH RELIEVA, respectively. This new line of artificial tear formulations is intended for contact lens wearers and was developed to reduce discomfort caused by eye dryness and to stop irritation.
  • On 5 November 2022, I-MED Pharma announced the launch of an innovative dry eye product portfolio in the United States. A company that offers a wide range of products, such as I-DROP artificial tears and I-LID ‘N LASH ocular hygiene cleaners.

Buy Now: https://www.futuremarketinsights.com/checkout/18329

Key Segments:

By Product Type:

  • Glycerine Tears
  • Cellulose Tears
  • Oil-based Emulsion Tears
  • Polyethylene Glycol-based Tears
  • Sodium Hyaluronate Based Artificial Tears
  • Propylene Glycol-based Tears

By Dosage Form:

  • Solution
  • Ointment
  • Emulsion
  • Gel
  • Spray
  • Suspensions

By Formulation:

  • Preservative Based
  • Non-Preservative Based

By Indication:

  • Dry Eye Syndrome
  • Allergies
  • Infections
  • UV & Blue Light Protection
  • Contact Lens Moisture Retention
  • Others

By Distribution channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Ophthalmic Stores

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East and Africa (MEA)

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

Explore Future Market Insights, Inc. Extensive Coverage in Healthcare Market Domain:

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: [email protected]
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

Primary Logo

Originally published at https://www.einpresswire.com/article/670289078/artificial-tears-market-growth-accelerating-with-increasing-prevalence-of-dry-eye-syndrome-and-development-in-clinical-research-future-market

- Part of VUGA -digital marketing

latest articles

gossip news

explore more

fashion tv watch free